Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials
Author:
Affiliation:
1. Dana-Farber Cancer Institute; Boston Massachusetts
2. Princess Margaret Cancer Centre; Toronto Canada
3. AstraZeneca; Wilmington Delaware
4. UCL Cancer Institute; University College London; London United Kingdom
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.29082/fullpdf
Reference58 articles.
1. Cancer statistics, 2014;Siegel;CA Cancer J Clin,2014
2. Optimal chemotherapy treatment for women with recurrent ovarian cancer;Fung-Kee-Fung;Curr Oncol,2007
3. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial;Parmar;Lancet,2003
4. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature;Gadducci;Crit Rev Oncol Hematol,2005
5. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG;Pfisterer;J Clin Oncol,2006
Cited by 63 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial;Annals of Oncology;2024-09
2. Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward;eClinicalMedicine;2024-09
3. Real-world Study on the Effect of PARPi as Maintenance Therapy on Platinum Sensitivity after First- and Second-line Chemotherapy in Patients with Recurrent High-grade Serous Epithelial Ovarian Cancer;Current Cancer Drug Targets;2024-07
4. Real-world effectiveness of CDK4/6 inhibitors on patients with HR+/HER2– advanced breast cancer in South Korea, focusing on underrepresented patients;Current Medical Research and Opinion;2024-05-09
5. A Comprehensive Review on Current Treatments and Challenges Involved in the Treatment of Ovarian Cancer;Current Cancer Drug Targets;2024-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3